ClinicalTrials.gg
RecruitingNCT06452732Updated Dec 31, 2025

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

An observational study in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Peking University People's Hospital. Recruiting at 2 sites in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
283
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.

Started
2024
with 1 other
Observational
3 of 20
3 open now
Primary completion
2026-06
later than 5 of 15 live
Registered
10th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is one of 2 that started in 2024, is one of 3 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 10th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, or all of them as a file.
02

Study summary

Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study was an exploratory study in search of new biomarkers, based on the previous literature, the recurrence rates of pre-transplant MRD (+) and MRD (-) in pediatric AML were 41% and 23.8% respectively (Br J Haematol.2024;204:585-594), with the ratio of patients in the two groups being 1:1.The calculation was done using PASS 15.0 assuming a two-sided test of α=0.05 and a test efficacy of = 1-β=80%, with the number of people needed being 226, taking into account a 20% censoring rate, the final total sample size was 283 patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnoses candidates with acute myeloid leukemia.
  • Lower than or equal to 18 years-old;
  • Subjects are able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Subjects who cannot comply with the study;
  • Subjects with severe cardiac disease (\<50% ), liver disease (total >34umol/L, and AST>1.5×upper limit normal) or kidney disease (Serum creatinine>130umol/L).
  • Subjects with severe infection.
  • Subjects with other conditions that cannot receive chemotherapy or transplantation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
283 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • MRD monitoring

    Other: MFC for the determination of leukemia stem cell

Interventions

  • OtherMFC for the determination of leukemia stem cell

    MFC for the determination of leukemia stem cell

06

What researchers measure

Primary outcomes

  1. The primary end point was cumulative incidences of relapse (CIR)

    Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites. Time to relapse was defined from the date of diagnosis to the date of disease recurrence. Patients exhibiting minimal residual disease were not classified as having relapsed.

    Time frame: 2 years

Secondary outcomes

  1. Leukemia free survival (LFS)

    Leukimia-free survival was defined as days from diagnosis to disease progression after transplantation.

    Time frame: 2 years

  2. Overall survival (OS)

    Overall survival referred to patients who survived until the final follow-up time point.

    Time frame: 2 years

  3. Non-relapse mortality (NRM)

    Non-relapse mortality was defined as all causes of death other than those related directly to malignant disease itself, occurring at any time after CR.

    Time frame: 2 years

  4. Transplant related mortality (TRM)

    Transplant-related mortality was defined as all causes of death other than those related directly to malignant disease itself, occurring at any time after transplantation.

    Time frame: 2 years

  5. Acute GVHD

    Acute GVHD was defined and graded from 0 to IV based on the pattern and severity of organ involvement\[Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. 2nd edn. Blackwell Science: Boston, MA, USA, 1999, pp 515-536.\]; grades III-IV aGVHD manifest as serious clinical features on the skin, liver and/or gut.

    Time frame: 2 years

  6. Chronic GVHD

    Chronic GVHD was defined and graded according to the National Institute of Health criteria:\[Biol Blood Marrow Transplant,2005,11: 945\] that is, mild cGVHD reflects the involvement of no more than 1 or 2 organs/sites (except for lung) with a maximum score of 1; moderate cGVHD involves at least 1 organ/site with a score of 2 or ≥3 organs/sites with a score of 1 (or lung score 1); and severe cGVHD is diagnosed when a score of 3 is given to any organ (or lung score 2). The diagnosis is mainly based on clinical manifestations.

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2026, 19 months after the start.

Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 19 months is below that.

Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 11, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06452732
Responsible party
Chang Yingjun (Chief Physician, Peking University People's Hospital) — Principal investigator
First posted
Jun 11, 2024
Start date
Nov 1, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Yingjun Chang Y Prof. Ying-Jun Chang Chang
Contact
rmcyj@bjmu.edu.cn
8610-88325949

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion